| HOME >> MEDICINE >> TECHNOLOGY |
-2,750,059Purchases of held-to-maturity marketable securities
-(3,840,016)Purchases of available-for-sale marketable securities
(3,218,286)-Purchases of property, plant and equipment
(73,902)(70,865)Purchase of intangible assets
(4,440)(10,405)Net cash provided by investing activities
23,372328,773Cash flows from financing activities:Net proceeds from exercise of options
-126,550Net cash provided by financing activities
-126,550Effect of exchange rate changes on cash and cash equivalents
(18,642)5,575Net decrease in cash and cash equivalents
(696,971)(902,632)Cash and cash equivalents at beginning of year
4,653,2266,063,573Cash and cash equivalents at end of year
$3,956,255$5,160,941Supplemental disclosure of cash flow information: Cash paid during the period for income tax
$18,592$8,968
Non-GAAP Financial Measures: The following table reconciles our operating loss calculated in accordance with accounting principles generally accepted in the U.S. (GAAP) to non-GAAP financial measures that exclude non-cash charges for share-based compensation, and depreciation and amortization expenses from gross profit, operating expenses and operating loss. The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP. We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies. Therefore, our non-GAAP financial measures may not be comparable to those used by other companies. We have described the reconciliations of each of our non-GAAP financial measures described above to the most directly comparable
'/>"/>
| SOURCE Uroplasty, Inc. Copyright©2012 PR Newswire. All rights reserved |